The GPHN Knockout NCI-H1975 Polyclonal Cells constitute a human lung adenocarcinoma polyclonal knockout cell population generated via CRISPR/Cas9-mediated disruption of the GPHN gene. This product comprises a heterogeneous pool of NCI-H1975 cells carrying targeted gene edits, enabling loss-of-function studies of gephyrin in a metastatic non-small cell lung cancer (NSCLC) background. The polyclonal format provides a robust, population-level model for examining gephyrin-dependent cellular processes without clonal isolation artifacts, and it is suitable for applications requiring stable gene disruption in epithelial cancer contexts. Researchers can employ these cells to interrogate gephyrin??s scaffolding and enzymatic roles in an EGFR-mutant adenocarcinoma environment.
Derived from a pleural effusion of a treatment-na?ve patient, the NCI-H1975 host cell line harbors activating EGFR L858R and T790M mutations, conferring constitutive kinase signaling and sensitivity to tyrosine kinase inhibitors. This cell line is a well-characterized model for advanced NSCLC, displaying metastatic properties and dysregulated growth factor pathways. The parental cells express gephyrin, which may exhibit non-canonical functions in epithelial cells beyond its classical postsynaptic roles. The knockout model enables dissection of gephyrin??s contributions to tumor cell biology, including its potential interplay with oncogenic EGFR and mTOR signaling.
Gephyrin, encoded by GPHN, is a multifunctional scaffold protein essential for clustering inhibitory glycine receptors (GLRA1/GLRB) and GABA_A receptors (e.g., GABRA1, GABRB2, GABRG2) at postsynaptic sites, and it simultaneously catalyzes the final step in molybdenum cofactor (MoCo) biosynthesis. Its activity is regulated by upstream signals including glycine, GABA, the guanine nucleotide exchange factor collybistin (ARHGEF9), PKA, CaMKII, and mTORC1. Gephyrin interacts directly with collybistin, neuroligin-2 (NLGN2), DYNLL1, and PIN1 to stabilize receptor clusters, while its MoCo synthetic domain supports MOCS1 and MOCS2. Disruption of GPHN in this model thus perturbs both inhibitory neurotransmission-related scaffolding and MoCo-dependent metabolic pathways.
In the NCI-H1975 background, gephyrin knockout likely abolishes glycine and GABA_A receptor anchoring, potentially altering chloride homeostasis and cellular excitability, though these properties are less defined in non-neuronal cancer cells. More critically, gephyrin??s enzymatic role in MoCo synthesis and its links to the ubiquitin-proteasome system and mTOR signaling may influence protein quality control and autophagy. The EGFR T790M mutation drives mTORC1 activation, and gephyrin loss could modulate downstream mTOR effectors such as p-S6K1, thereby affecting proliferation and drug sensitivity. This model thus provides a unique platform for studying gephyrin??s non-synaptic functions in lung adenocarcinoma, including its potential impact on EGFR inhibitor responses.
Key applications include investigating gephyrin??s role in NSCLC proliferation and autophagy via assays such as MTT and LC3B flux analysis, evaluating altered sensitivity to EGFR inhibitors like osimertinib, and examining mTOR pathway activity through phospho-S6K1 immunoblotting. Researchers may also reconstitute inhibitory synapse components to study scaffolding dynamics or probe MoCo synthetic activity. The cells are suitable for Western blotting, RT-qPCR, and immunofluorescence to validate gephyrin disruption and downstream effects. This knockout model aids in linking gephyrin to cancer cell signaling, metabolic adaptation, and therapeutic vulnerability. For detailed technical inquiries, please contact Ascent Research.
